Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OPTIFAST II is a medically supervised total meal replacement (TMR) program and low-calorie formula diet (LCD) developed by Nestlé Health Science. The program is primarily indicated for the management of obesity and its associated comorbidities, such as Type 2 Diabetes Mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). It typically provides approximately 800 kcal per day through nutritionally complete sachets (shakes, soups, and bars) that replace all conventional food intake during an initial intensive weight-loss phase. This significant caloric restriction induces rapid weight loss, improves glycemic control (HbA1c), and enhances insulin sensitivity. Additionally, OPTIFAST II is frequently utilized in preoperative settings to reduce liver volume and peri-organ fat, thereby improving surgical visualization and reducing perioperative risks in bariatric and major non-bariatric procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OPTIFAST II.